MBX Biosciences Q2 2026 Financial and Clinical Update
MBX Biosciences Inc. (NASDAQ:MBX) announced its financial results for the quarter ended June 30, 2026, reporting a net loss of $37.1 million, equivalent to a loss of $0.78 per share, compared with a net loss of $19.4 million in the same quarter of the prior year. Research and development expenses increased to $31.0 million from $17.7 million year‑over‑year, driven by start‑up costs for the Phase 3 canvuparatide trial, ongoing Phase 2 extension work, and the initiation of the Phase 1 MBX 4291 trial. General and administrative expenses rose to $9.9 million from $4.1 million YoY, reflecting higher personnel costs and infrastructure expansion. In pre‑market trading, MBX shares edged up 0.2%.
On the clinical front, the company disclosed initial Phase 1 data for MBX 4291, a GLP‑1/GIP co‑agonist prodrug targeting obesity. The first multiple ascending dose cohort achieved a mean weight loss of 7% after eight weeks, with the drug generally well tolerated. MBX expects to release data from the first cohort of the 12‑week portion of the trial in the fourth quarter of 2026. Additionally, MBX nominated MBX 6180, a GLP‑1/GIP/GCG triple‑agonist prodrug designed for once‑monthly dosing, as a development candidate. For canvuparatide, its once‑weekly therapy for chronic hypoparathyroidism, the company activated clinical trial sites for the Phase 3 pivotal trial and is currently recruiting participants.
Cash, cash equivalents, and marketable securities stood at $418.6 million as of June 30, 2026, which the company expects will be sufficient to fund operations into 2029.
Quote: "The second quarter was highlighted by important milestones across our pipeline, including a first look at clinical data for MBX 4291 supporting its potential for true once‑monthly dosing in obesity," said Steve Hoerter, Chairman and Chief Executive Officer.